Foreign Exchange Controls and Payment for Medical Device Imports in Myanmar

1. Key takeaways

Medical device imports into Myanmar face a constraint that is non-technical yet highly consequential: the central bank’s foreign exchange controls. A local importer’s purchase of US dollars or euros to pay overseas suppliers requires approval, and this causes delays in payment. The constraint operates entirely outside the regulatory dossier, yet it can hold up the commercial side of a transaction whose regulatory side is complete.

GRZAN insight: the impact of the foreign exchange constraint does not appear at the registration stage but at the commercial delivery stage. Companies should state the payment terms clearly in the contract (for example, letter of credit or prepayment), and allocate the uncertainty of foreign exchange approval explicitly to one contractual party rather than leaving it, by default, to be borne by the supplier. The foreign exchange essentials can be remembered as: 1 controlling authority, 2 principal impacts, and 1 set of payment terms arrangements.

• 1 controlling authority — the Central Bank of Myanmar, which subjects foreign currency purchases for supplier payments to approval.
• 2 principal impacts — delayed payments to overseas suppliers, and significant exchange rate risk on contracts denominated in MMK.
• 1 set of payment terms — price in USD where possible, and fix payment conditions such as letter of credit or prepayment in the contract.

2. Legal basis

The table below consolidates the elements of the foreign exchange and payment framework. It identifies the controlling authority and the content of the control, records the principal impact, lists the recommended responses as practical estimates, and links the foreign exchange regime to the lengthened import licence processing times observed in 2026 and to the currency risk carried by contracts denominated in local currency.

3. Expert insights

Insight 1: foreign exchange approval is a delivery risk, not a compliance risk. It does not affect whether the registration can be approved, but it affects whether the goods can be paid for and collected as planned. A project can be fully compliant — registered, licensed, documented — and still stall because the funds to pay the supplier are waiting for approval. Teams should therefore track foreign exchange as a delivery-line item, not as part of the regulatory checklist.

Insight 2: the contract is the principal instrument for allocating foreign exchange approval risk. Through clearly stated payment terms, the consequences of approval delay can be distributed reasonably between the two parties. If the contract is silent, the delay falls by default on whoever is waiting for the money — usually the supplier — which is rarely the allocation the parties would have chosen deliberately. Writing the terms down converts an ambient policy risk into a managed contractual risk.

Insight 3: pricing in USD avoids part of the exchange rate risk. Compared with the MMK, whose exchange rate fluctuates considerably, USD pricing is more controllable for the exporter. The supplier’s costs are largely incurred in dollars, so denominating the invoice in the same currency removes a conversion layer whose volatility neither party can control, leaving the remaining risk where it can be priced and managed.

Insight 4: foreign exchange controls compound with the extended import licensing, amplifying the uncertainty of the delivery cycle. Both stem from the policy orientation of preserving foreign exchange reserves. Because the two delays share one policy root, they tend to move together and to reinforce each other: a shipment can wait simultaneously for the licence and for the approval to pay, and neither waiting period can be estimated from the other. Delivery schedules should carry a margin sized for the combination, not for either risk alone.

Insight 5: the foreign exchange constraint does not change the registration obligations themselves. Companies must still complete FDA registration and Ministry of Commerce licensing; the foreign exchange problem provides no grounds for exemption. The two tracks must proceed in parallel even when payment is delayed, because an approval that pauses the money does not pause the compliance clock, and falling behind on registration while funds are pending only deepens the eventual backlog.

4. Practical recommendations

• State the payment terms and currency clearly in the contract. Give priority to pricing in USD.
• Agree on a mechanism for handling foreign exchange approval delays. Define responsibilities and remedial measures in advance.
• Reserve a time buffer for foreign exchange approval. Do not build funding plans on the assumption that transfers arrive immediately.
• Maintain communication with the local importer on approval progress. Establish a mechanism for periodic confirmation.
• Do not treat foreign exchange problems as a reason to delay registration or reporting. Advance the two tracks in parallel.

5. Verification checklist

• □ Stated the payment terms and currency clearly in the contract
• □ Agreed on a mechanism for handling foreign exchange approval delays
• □ Reserved a time buffer for foreign exchange approval
• □ Established a communication mechanism with the importer on approval progress
• □ Confirmed that foreign exchange constraints do not affect registration obligations
• □ Recorded the date on which the foreign exchange policy was queried
• □ Incorporated the registration ledger into management

Regulatory information verified as of 29 October 2026.

In the Southeast Asian market, GRZAN’s core strengths concentrate on three points. First, distinguishing the legislative progress of each ASEAN member state’s dedicated medical device law — Singapore, Malaysia, Thailand, Indonesia, the Philippines, Vietnam and others have each established their own written medical device regulatory framework, whereas Myanmar has not yet enacted a dedicated law; its rules are assembled from three layers: the technical framework of the ASEAN Medical Device Directive, administrative guidance from the competent authority, and the catch-all authorisation of the Public Health Law 1972, so compliance certainty is markedly lower than in markets where dedicated legislation is complete. Second, local authorised representative services, in which GRZAN can act as the statutory representative of the manufacturer in these countries, carrying registration submissions, regulatory communications, and post-market reporting obligations. Third, quality system and laboratory testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com